Johnson & Johnson (NYSE:JNJ) Shares Acquired by Richard C. Young & CO. LTD.

Richard C. Young & CO. LTD. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 74,683 shares of the company’s stock after buying an additional 467 shares during the period. Richard C. Young & CO. LTD.’s holdings in Johnson & Johnson were worth $10,801,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. AMF Tjanstepension AB boosted its stake in Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after purchasing an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC bought a new position in Johnson & Johnson during the third quarter valued at about $209,000. Wealth Group Ltd. acquired a new position in Johnson & Johnson during the third quarter worth about $213,000. ORG Wealth Partners LLC bought a new stake in Johnson & Johnson in the third quarter worth about $226,000. Finally, Wedge Capital Management L L P NC boosted its position in shares of Johnson & Johnson by 2.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 4,039 shares of the company’s stock valued at $655,000 after purchasing an additional 86 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.3 %

Shares of NYSE:JNJ opened at $156.18 on Wednesday. The firm has a fifty day moving average of $147.40 and a two-hundred day moving average of $156.04. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The firm has a market capitalization of $376.02 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on JNJ. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Barclays lifted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Raymond James decreased their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Stifel Nicolaus cut their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.